Urinary excretion of growth factors in patients with ovarian cancer.
The levels of epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) were analysed in 24-h urine samples from patients with ovarian malignancies, benign ovarian tumours, and healthy controls by specific radioimmunoassays. No significant difference in total urinary immunoreactive EGF excretion between the groups was detected. However, 79% (23/29) of the patients with ovarian carcinomas excreted TGF-alpha (median 12.6 pmol/24 h), whereas only 17% (2/12) of the patients with benign ovarian tumours and 23% (3/13) of the controls did so. The difference between cancer patients and controls was highly significant (P < 0.001). Analyses of the urine samples separated by gel filtration revealed a greater molecular heterogeneity of EGF and TGF-alpha in cancer patients than in controls. High and low molecular weight forms of EGF were able to bind to the EGF receptor and to induce anchorage-independent growth. After surgical reduction of the tumour, a distinct decrease of urinary high molecular weight forms was observed. Thus, some macromolecular growth factors seem to be associated with epithelial ovarian carcinomas.
Feldkämper
M
M
Department of Obstetrics and Gynecology, Philipps University, Marburg, Germany.
Enderle-Schmitt
U
U
Hackenberg
R
R
Schulz
K D
KD
D014408:Biomarkers, Tumor / Q000652:urine*; D004815:Epidermal Growth Factor / Q000737:chemistry / Q000378:metabolism / Q000652:urine*; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D008970:Molecular Weight; D010051:Ovarian Neoplasms / Q000601:surgery / Q000652:urine*; D011184:Postoperative Period; D011863:Radioimmunoassay; D011869:Radioligand Assay; D016211:Transforming Growth Factor alpha / Q000737:chemistry / Q000378:metabolism / Q000652:urine*
D014408:Biomarkers, Tumor; D016211:Transforming Growth Factor alpha; D004815:Epidermal Growth Factor; D066246:ErbB Receptors